130 related articles for article (PubMed ID: 33565809)
1. Neoadjuvant Checkpoint Blockade in Lynch Syndrome-Related Pancreatic Adenocarcinoma.
Childers BG; Valasek MA; Patel H; Lowy AM
Pancreas; 2021 Feb; 50(2):e22-e24. PubMed ID: 33565809
[No Abstract] [Full Text] [Related]
2. Single-Agent Immunotherapy for Two Types of Cancer in One Patient.
Musher B; Rahal A
Ann Intern Med; 2019 Feb; 170(3):210-211. PubMed ID: 30264147
[No Abstract] [Full Text] [Related]
3. Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Patil NR; Khan GN
Am J Case Rep; 2020 Jul; 21():e923803. PubMed ID: 32658872
[TBL] [Abstract][Full Text] [Related]
4. Two Months of Therapy: A Case of Pathologic Complete Response to Chemoimmunotherapy in a Patient With Metastatic Colorectal Cancer.
Armstrong S; Al-Ghawi H; Helft P; House MG; Spittler AJ; Wu HH; Shahda S
Clin Colorectal Cancer; 2018 Jun; 17(2):e229-e232. PubMed ID: 29311032
[No Abstract] [Full Text] [Related]
5. Immune oncology and neuroendocrine tumors.
Chauhan A; Anthony L
Ann Oncol; 2017 Sep; 28(9):2322-2323. PubMed ID: 28505259
[No Abstract] [Full Text] [Related]
6. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
7. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline
Lundy J; McKay O; Croagh D; Ganju V
JCO Precis Oncol; 2022 Jan; 6():e2100437. PubMed ID: 35085003
[No Abstract] [Full Text] [Related]
8. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Zhang Z; Ji S; Hu Q; Zhuo Q; Liu W; Xu W; Liu W; Liu M; Ye Z; Fan G; Xu X; Yu X; Qin Y
Clin Transl Med; 2021 Aug; 11(8):e398. PubMed ID: 34459132
[No Abstract] [Full Text] [Related]
9. Adjuvant pertuzumab improves early breast cancer outcomes.
Das M
Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
[No Abstract] [Full Text] [Related]
10. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
Li R; Spiess PE; Gilbert SM; Necchi A
Eur Urol; 2019 Jul; 76(1):4-6. PubMed ID: 30833139
[TBL] [Abstract][Full Text] [Related]
11. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.
Artinyan A; Anaya DA; McKenzie S; Ellenhorn JD; Kim J
Cancer; 2011 May; 117(10):2044-9. PubMed ID: 21523715
[TBL] [Abstract][Full Text] [Related]
13. Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Yang A; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):585-601. PubMed ID: 25686370
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Shamseddine A; Zeidan YH; El Husseini Z; Kreidieh M; Al Darazi M; Turfa R; Kattan J; Khalifeh I; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Charafeddine M; Geara F
Radiat Oncol; 2020 Oct; 15(1):233. PubMed ID: 33028346
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.
Wong HL; Christie M; Gately L; Tie J; Lee B; Semira C; Lok SW; Wong R; Gibbs P
Future Oncol; 2018 Nov; 14(26):2725-2739. PubMed ID: 30004261
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
[No Abstract] [Full Text] [Related]
17. Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer.
Hill A; Gong J; Wilczynski S; Mirza R; Erhunmwunsee L; Salgia R
J Oncol Pract; 2018 Sep; 14(9):569-571. PubMed ID: 30044685
[No Abstract] [Full Text] [Related]
18. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC; Orlowski RJ; Xu X; Mick R; George SM; Yan PK; Manne S; Kraya AA; Wubbenhorst B; Dorfman L; D'Andrea K; Wenz BM; Liu S; Chilukuri L; Kozlov A; Carberry M; Giles L; Kier MW; Quagliarello F; McGettigan S; Kreider K; Annamalai L; Zhao Q; Mogg R; Xu W; Blumenschein WM; Yearley JH; Linette GP; Amaravadi RK; Schuchter LM; Herati RS; Bengsch B; Nathanson KL; Farwell MD; Karakousis GC; Wherry EJ; Mitchell TC
Nat Med; 2019 Mar; 25(3):454-461. PubMed ID: 30804515
[TBL] [Abstract][Full Text] [Related]
19. Pathological complete response after neoadjuvant pembrolizumab and radiation.
Mynard JN; Conry RM; De Los Santos J; Gordetsky JB; Contreras CM
Clin Exp Dermatol; 2019 Jul; 44(5):570-573. PubMed ID: 30402885
[No Abstract] [Full Text] [Related]
20. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
Gambichler T; Doerler M; Scheel CH
Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
[No Abstract] [Full Text] [Related]
[Next] [New Search]
